Patient-Reported Outcomes in Systemic Light-Chain Amyloidosis

Conclusion: Patients with AL amyloidosis have a worse HRQoL at diagnosis compared to US cancer and general adult population. Deficit in HRQoL was most prominent in the FWB domain of FACT-G and GPH domain of PROMIS-GH. Most domains of FACT-G and PROMIS-GH had strong and significant correlation. Patients achieving a CR to first-line therapy had significantly superior HRQoL at all FACT-G domains. Clinical trials in AL amyloidosis should include patient-reported HRQoL as a key endpoint and focus on the domains of physical health and functioning to assess meaningful benefit of novel therapies. Psychometric validation of FACT-G and PROMIS-GH in AL amyloidosis would be helpful in generating robust PRO data in future studies.DisclosuresMajhail: Anthem, Inc.: Consultancy; Incyte: Honoraria; Atara: Honoraria.

Source: Blood - November 21, 2018 Category: Hematology Authors: Chakraborty, R., Rybicki, L., Samaras, C. J., Faiman, B. M., Valent, J., Majhail, N. S. Tags: 904. Outcomes Research-Malignant Conditions: Poster III Source Type: research